Physician profile

Herman Dick

Bloomington, IL

NPI 1891891370

$1,946.80

in general payments reported to CMS, 2019-2025

26 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $401.89 2019-2021
Alexion Pharmaceuticals, INC. $158.87 2019-2020
Janssen Pharmaceuticals, INC $145.29 2021
Biohaven Pharmaceuticals, INC. $115.10 2020-2021
Neurocrine Biosciences, INC. $113.28 2019-2021
Biohaven Pharmaceutical Holding Company LTD. $105.23 2022
Jazz Pharmaceuticals INC. $104.43 2020-2022
Emd Serono, INC. $102.79 2019-2021
Biogen, INC. $94.07 2019
Grifols USA, LLC $88.74 2019
Mallinckrodt Hospital Products INC. $79.15 2020-2021
Abbvie INC. $72.90 2021-2022
Genzyme Corporation $64.13 2019
E.R. Squibb & Sons, L.L.C. $44.86 2020-2021
Genentech USA, INC. $33.41 2021
Show all 26 companies
CompanyGeneral paymentsYearsTop products
Livanova USA, INC. $33.00 2020-2022
Teva Pharmaceuticals USA, INC. $32.00 2019-2020
Amgen INC. $27.29 2019
Sk Life Science, INC. $20.94 2021
Csl Behring $19.92 2021
Impel Pharmaceuticals INC. $18.70 2022
Celgene Corporation $18.11 2021
Kyowa Kirin, INC. $15.59 2022
Amneal Pharmaceuticals LLC $14.29 2019
Ucb, INC. $11.64 2020
Acadia Pharmaceuticals INC $11.18 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Herman Dick

$1,946.80

in general payments reported 2019-2025

Years
2019-2022
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/40386/herman-dick

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.